Pozen Inc (POZN) 8.36 $POZN
Pozen (POZN) Crosses Above $7.59 SqueezeTrigger Price and is Undervalued According to WealthMakers.com Report
M2 - Fri Apr 10, 11:49AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued a new research report today on Pozen (NASDAQ: POZN). The report highlights the short term bullish pattern that has emerged, the short squeeze starting at $7.59 and the projected fundamental valuation of $17.65.
POZN: 8.36 (+0.22)
BUYINS.NET: POZN SqueezeTrigger Price is $7.59. There is $19,544,763 That Short Sellers Still Need To Cover.
M2 - Mon Apr 06, 12:17PM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring POZEN INC. (NASDAQ
OZN) in real time and just received an alert that POZN is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 2568300 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $7.59. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
POZN: 8.36 (+0.22)
BUYINS.NET: POZN SqueezeTrigger Price is $7.59. There is $19,519,080 That Short Sellers Still Need To Cover.
M2 - Fri Mar 27, 4:28AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring POZEN INC. (NASDAQ OZN) in real time and just received an alert that POZN is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 2568300 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $7.59. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
POZN: 8.36 (+0.22)
Pozen (POZN) is Undervalued With a Short Squeeze Starting
M2 - Mon Mar 23, 10:05AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has updated its research report today on Pozen (NASDAQ: POZN). The report highlights the short term bullish pattern that has emerged, the SqueezeTrigger Price of $7.59 and the projected short squeeze valuation of $17.65 per share.
POZN: 8.36 (+0.22)
POZEN (POZN) Downgraded From Buy to Hold
at The Street - Wed Mar 11, 12:43PM CDT
POZEN (POZN) has been downgraded by TheStreet Ratings from Buy to Hold with a ratings score of C+.
POZN: 8.36 (+0.22)
POZEN's CEO John Plachetka on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Mar 09, 3:37PM CDT
POZN: 8.36 (+0.22)
Pozen (POZN) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Mar 09, 9:55AM CDT
POZN: 8.36 (+0.22)
Pozen ups revenues 215% in FY14
Seeking Alpha - at Seeking Alpha - Mon Mar 09, 6:52AM CDT
POZN: 8.36 (+0.22)
Pozen posts 4Q profit
Automated Insights - Mon Mar 09, 6:51AM CDT
CHAPEL HILL, N.C. (AP) _ Pozen Inc. (POZN) on Monday reported fourth-quarter net income of $7 million, after reporting a loss in the same period a year earlier.
POZN: 8.36 (+0.22)
Pozen beats by $0.04, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Mar 09, 6:33AM CDT
POZN: 8.36 (+0.22)
POZEN Reports Fourth Quarter and Year End 2014 Results
Business Wire - Mon Mar 09, 6:30AM CDT
--- Updates Anticipated Commercialization Timing -
POZN: 8.36 (+0.22)
Notable earnings before Monday’s open
Seeking Alpha - at Seeking Alpha - Sun Mar 08, 4:30PM CDT
WUBA: 75.56 (+3.20), POZN: 8.36 (+0.22), BITA: 57.15 (+0.89), LITB: 4.98 (unch)
POZEN wins VIMOVO related patent in the US
M2 - Thu Feb 05, 5:52AM CST
Pharmaceutical company POZEN (NasdaqGS OZN) reported on Wednesday the receipt of a patent from the US Patent and Trademark Office (USPTO) entitled "Method for Treating a Patient at Risk for Developing an NSAID-associated Ulcer" expiring in October 2031.
POZN: 8.36 (+0.22)
POZEN Announces Issuance of VIMOVO(R) Related Patent by the United States Patent and Trademark Office
Business Wire - Wed Feb 04, 3:06PM CST
POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced the issuance of a patent by the United States Patent and Trademark Office (USPTO) entitled "Method for Treating a Patient at Risk for Developing an NSAID-associated Ulcer" that relates to VIMOVO(R) (naproxen/esomeprazole magnesium) delayed release tablets in patients taking low dose aspirin. The patent expires in October 2031.
HZNP: 30.96 (+0.10), POZN: 8.36 (+0.22)
Nasdaq stocks posting largest percentage decreases
AP - Tue Jan 13, 5:15PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
DISCK: 31.69 (-0.08), ARWR: 6.88 (+0.14), AFMD: 7.94 (+0.11), TFM: 38.35 (-0.02), SRPT: 13.52 (+0.04), DISCB: 33.69 (-0.19), DISCA: 33.53 (+0.05), POZN: 8.36 (+0.22), PEIX: 12.25 (-0.30), GFN: 7.82 (+0.04), HLSS: 17.20 (+0.02), DXPE: 44.71 (-0.95), OBAS: 7.04 (-0.29)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 4:35PM CST
NBIX: 43.23 (-0.43), ROC: 79.20 (+0.33), RUSL: 30.99 (+0.53), RUSS: 7.47 (-0.15), EHIC: 10.38 (+0.08), BURL: 55.82 (+0.09), POZN: 8.36 (+0.22), EXK: 1.86 (-0.09), SEM: 15.29 (+0.27), MCO: 107.23 (+1.24)
Pozen and J&J division cut the cord in migraine drug deal in South America
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 6:44AM CST
POZN: 8.36 (+0.22)
Pozen (POZN) Crosses Above $7.59 SqueezeTrigger Price and is Undervalued According to WealthMakers.com Report
M2 - Fri Apr 10, 11:49AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued a new research report today on Pozen (NASDAQ: POZN). The report highlights the short term bullish pattern that has emerged, the short squeeze starting at $7.59 and the projected fundamental valuation of $17.65.
POZN: 8.36 (+0.22)
BUYINS.NET: POZN SqueezeTrigger Price is $7.59. There is $19,544,763 That Short Sellers Still Need To Cover.
M2 - Mon Apr 06, 12:17PM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring POZEN INC. (NASDAQ
OZN) in real time and just received an alert that POZN is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 2568300 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $7.59. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com . POZN: 8.36 (+0.22)
BUYINS.NET: POZN SqueezeTrigger Price is $7.59. There is $19,519,080 That Short Sellers Still Need To Cover.
M2 - Fri Mar 27, 4:28AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring POZEN INC. (NASDAQ
OZN) in real time and just received an alert that POZN is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 2568300 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $7.59. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com . POZN: 8.36 (+0.22)
Pozen (POZN) is Undervalued With a Short Squeeze Starting
M2 - Mon Mar 23, 10:05AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has updated its research report today on Pozen (NASDAQ: POZN). The report highlights the short term bullish pattern that has emerged, the SqueezeTrigger Price of $7.59 and the projected short squeeze valuation of $17.65 per share.
POZN: 8.36 (+0.22)
POZEN (POZN) Downgraded From Buy to Hold
at The Street - Wed Mar 11, 12:43PM CDT
POZEN (POZN) has been downgraded by TheStreet Ratings from Buy to Hold with a ratings score of C+.
POZN: 8.36 (+0.22)
POZEN's CEO John Plachetka on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Mar 09, 3:37PM CDT
POZN: 8.36 (+0.22)
Pozen (POZN) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Mar 09, 9:55AM CDT
POZN: 8.36 (+0.22)
Pozen ups revenues 215% in FY14
Seeking Alpha - at Seeking Alpha - Mon Mar 09, 6:52AM CDT
POZN: 8.36 (+0.22)
Pozen posts 4Q profit
Automated Insights - Mon Mar 09, 6:51AM CDT
CHAPEL HILL, N.C. (AP) _ Pozen Inc. (POZN) on Monday reported fourth-quarter net income of $7 million, after reporting a loss in the same period a year earlier.
POZN: 8.36 (+0.22)
Pozen beats by $0.04, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Mar 09, 6:33AM CDT
POZN: 8.36 (+0.22)
POZEN Reports Fourth Quarter and Year End 2014 Results
Business Wire - Mon Mar 09, 6:30AM CDT
--- Updates Anticipated Commercialization Timing -
POZN: 8.36 (+0.22)
Notable earnings before Monday’s open
Seeking Alpha - at Seeking Alpha - Sun Mar 08, 4:30PM CDT
WUBA: 75.56 (+3.20), POZN: 8.36 (+0.22), BITA: 57.15 (+0.89), LITB: 4.98 (unch)
POZEN wins VIMOVO related patent in the US
M2 - Thu Feb 05, 5:52AM CST
Pharmaceutical company POZEN (NasdaqGS
OZN) reported on Wednesday the receipt of a patent from the US Patent and Trademark Office (USPTO) entitled "Method for Treating a Patient at Risk for Developing an NSAID-associated Ulcer" expiring in October 2031. POZN: 8.36 (+0.22)
POZEN Announces Issuance of VIMOVO(R) Related Patent by the United States Patent and Trademark Office
Business Wire - Wed Feb 04, 3:06PM CST
POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced the issuance of a patent by the United States Patent and Trademark Office (USPTO) entitled "Method for Treating a Patient at Risk for Developing an NSAID-associated Ulcer" that relates to VIMOVO(R) (naproxen/esomeprazole magnesium) delayed release tablets in patients taking low dose aspirin. The patent expires in October 2031.
HZNP: 30.96 (+0.10), POZN: 8.36 (+0.22)
Nasdaq stocks posting largest percentage decreases
AP - Tue Jan 13, 5:15PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
DISCK: 31.69 (-0.08), ARWR: 6.88 (+0.14), AFMD: 7.94 (+0.11), TFM: 38.35 (-0.02), SRPT: 13.52 (+0.04), DISCB: 33.69 (-0.19), DISCA: 33.53 (+0.05), POZN: 8.36 (+0.22), PEIX: 12.25 (-0.30), GFN: 7.82 (+0.04), HLSS: 17.20 (+0.02), DXPE: 44.71 (-0.95), OBAS: 7.04 (-0.29)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 4:35PM CST
NBIX: 43.23 (-0.43), ROC: 79.20 (+0.33), RUSL: 30.99 (+0.53), RUSS: 7.47 (-0.15), EHIC: 10.38 (+0.08), BURL: 55.82 (+0.09), POZN: 8.36 (+0.22), EXK: 1.86 (-0.09), SEM: 15.29 (+0.27), MCO: 107.23 (+1.24)
Pozen and J&J division cut the cord in migraine drug deal in South America
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 6:44AM CST
POZN: 8.36 (+0.22)
